Enveric Biosciences (ENVB) - חוב לטווח ארוך להון

Enveric Biosciences is developing Psybrary cloud IT solutions to create precise psilocybin compounds, aiming to capture the B2B licensing niche. Serving as a valuation tool, this chart demonstrates the 0.00 metric. The business relies on the synthesis of psychedelic formulas to combat mental pathologies without inducing hallucinations. The current stage is characterized by a lack of profit and planned capital expenditure on scientific research, supported by a significant volume of accumulated funds.

Enveric Biosciences occupies a promising niche in the development of non-hallucinogenic psychedelics for the treatment of depression. This indicator compares liabilities with maturities exceeding one year against equity to determine the degree of financial autonomy. By analyzing the history of financial leverage regarding long-term debt, an investor assesses the risk of over-indebtedness. For an R&D company, such a capital structure is critical when financing costly research. A stable trend confirms the resilience of the business development strategy.